17 results about "Deoxyglucose" patented technology

The present disclosure provides methods and kits for detecting Group A Streptococcus in biological samples. More particularly, the present disclosure provides methods for enhancing the specificity and sensitivity of Group A Streptococcus immunoassays by including N-propionyl-D-glucosamine, 2-N-butanoyl-D-glucosamide, Bis-(2-(D-2-deoxy-glucosaminyl))-PEG3-amide, m-PEG4-glucosamine, m-PEG6-glucosamine, or m-PEG10-glucosamine. The methods and kits disclosed herein are thus useful for reliable and early diagnosis of streptococcal infections in a subject.

Provided herein is a dendrimer complex comprising a 2-deoxyglucose (2DG) dendrimer and a neuroactive agent conjugated to an outer surface of the dendrimer. The dendrimer complex may further include one or more imaging agents and / or radioligands conjugated to an outer surface of the dendrimer. Such complexes are useful in methods for detecting or treating neurological diseases or disorders.

The invention discloses an epilepsy focus detection method based on magnetic resonance imaging. The epilepsy focus detection method comprises the steps that MRI data and < 18 > F fluorescence deoxyglucose PET / CT scanning data of a patient before an operation are collected; processing the MRI data and the PET data; carrying out statistical analysis on the PET image, comparing a standard deviation with a normal database, and generating a QPET image; carrying out QPET-MAP (Quality Point of Emission Tomography Whether the cut QPET-MAP + area is mainly in the FCD type I or not is determined through postoperative pathological examination; and performing registration on the preoperative MRI and the postoperative MRI by using SPM12 software, and determining the excision integrity of the QPET-MAP + region. The QPET provides functional imaging data, and metabolic changes related to epilepsy are identified through quantitative analysis of PET scanning; the MAP provides structural imaging data, identifying a potential FCD by automated analysis of the MRI data; the detection rate of the FCD of the MRI negative epileptic is improved through the MAP. The detection sensitivity is improved, the specificity is also increased, and the epileptic focus is more accurately positioned. According to the invention, surgeons can be helped to more accurately position and cut epileptic lesions, and the operation effect is improved.

Provided herein are methods and pharmaceutical compositions for preventing or reducing frequency or severity of convulsions or seizures, particularly epileptic seizures by administration of a therapeutically effective amount of 2-deoxy-D-glucose (2-DG) in combination with a therapeutically effective amount of beta-hydroxybutyrate, or 2-DG with other ketones or metabolic intermediates that increase brain ketones. Also provided are methods and pharmaceutical compositions for reducing severity and progression of traumatic brain injury and deleterious sequelae resulting therefrom in an animal by administration of a therapeutically effective amount of 2-DG in combination with a therapeutically effective amount of beta-hydroxybutyrate, or 2-DG with other ketones or metabolic intermediates that increase brain ketones.

The application belongs to the field of biomedical technology, and aims to solve the problems of lack of metabolic typing characteristics in the current ESCC molecular typing method, lack of esophageal squamous cell carcinoma molecular typing method based on proteomics and metabolomics, and provides an esophageal squamous carcinoma ESCC molecular typing marker based on DIA proteomics and non-targeted metabolomics and its application. The marker is a combination of 4 proteins and 2 metabolites, the 4 proteins are: hexokinase 3 (HK3), Sec1 family domain protein 1 (SCFD1), septin 5 (SEPTIN5), and signal sequence receptor alpha subunit (SSR1); the 2 metabolites are creatine and 2-deoxy-D-glucose (2'DG). The application fills the gap of the molecular typing method based on proteomics and metabolomics in the field of esophageal squamous carcinoma research, and the proposed molecular typing model can be used as a method for diagnosis, treatment and prognosis evaluation of esophageal squamous carcinoma patients.

Provided are a method for producing a mesenchymal stem cell culture, a mesenchymal stem cell culture, a pharmaceutical composition containing a mesenchymal stem cell culture, and a method for producing a population of mesenchymal cells. This method for producing a mesenchymal stem cell culture includes a step (a) for culturing a tissue-derived sample containing a population of mesenchymal stem cells under serum starvation conditions or 2-deoxy-D-glucose (2-DG)-containing culture medium conditions to thereby separate a culture of mesenchymal stem cells that survived the serum starvation conditions or 2-DG-containing culture medium conditions. The population of mesenchymal stem cells is not exposed to growth conditions from after collection of the tissue-derived sample from an individual until culturing is performed under serum starvation conditions or 2-DG-containing culture medium conditions.

The utility model relates to the technical field of deoxidized glucose injection bottle plugs, in particular to deoxidized glucose injection bottle plug press sealing equipment which comprises a supporting assembly and a box body, the box body is arranged at the upper end of the supporting assembly, a box door is movably installed on one side of the box body, a fixing cover is arranged at the upper end of the box body, and a press sealing mechanism is arranged at the upper end of the box body. A first transmission rod is arranged at the output end of the hydraulic assembly; a sliding plate is arranged at one end of the first transmission rod; a press-sealing assembly is arranged at the lower end of the sliding plate; a second transmission rod is arranged in the press-sealing assembly; an adjusting mechanism is arranged in the box body, a first limiting sleeve is arranged in the adjusting mechanism, a first threaded rod is arranged on the first limiting sleeve, a first sliding sleeve is arranged on the first threaded rod, a first limiting rod is arranged on one side of the first sliding sleeve, and a first turbine is arranged at the bottom end of the first threaded rod.

The invention belongs to the technical field of microorganisms, and discloses a Saccharomyces cerevisiae DG-11 strain with low acetic acid yield, and the preservation number of the Saccharomyces cerevisiae DG-11 strain is CCTCC (China Center for Type Culture Collection) M 20251925. The strain is obtained by combining ARTP mutagenesis with 2-deoxyglucose (2-DG) resistance screening, and has the following characteristics that in simulated fruit juice fermentation, the yield of acetic acid is remarkably reduced compared with that of an original strain RV002; in the metabolic pathway, the activities of pyruvate decarboxylase (Pdc) and acetaldehyde dehydrogenase (Ald) are inhibited, and the activity of ethanol dehydrogenase (Adh) is enhanced, so that carbon metabolism is inclined to ethanol synthesis; meanwhile, the strain has excellent ethanol, high glucose and pH tolerance, and is stable in hereditary character. In addition, the content of acetic esters in the DG-11 fermentation liquor is reduced, and the content of part of ethyl esters and higher alcohols is increased, so that the flower and fruit aroma characteristics are favorably formed. The saccharomyces cerevisiae strain with excellent performance and low acetic acid yield is provided for fruit wine brewing, and the saccharomyces cerevisiae strain has important industrial application value.

Provided herein is a dendrimer complex comprising a 2-deoxy glucose (2DG) dendrimer and a neuroactive agent conjugated to an outer surface of the dendrimer. The dendrimer complex may further include one or more imaging agents and / or radioligands conjugated to an outer surface of the dendrimer. Such complexes are useful in methods for detecting or treating neurological diseases or disorders.

The application discloses a combined drug for treating tumors; aims to provide a treatment scheme for targeting transport of a chemotherapeutic drug and a metabolic drug, activating a tumor microenvironment, and treating tumor patients by combining chemotherapy, metabolic therapy and immunotherapy; and the technical key point is that an immune-activated biomimetic nanovesicle is used to load a chemotherapeutic drug, doxorubicin hydrochloride (DOX), and a sugar metabolism inhibitor, 2-deoxy-D-glucose (2-DG); wherein: the activated biomimetic nanovesicle highly expresses PD1 molecules, can competitively interact with PD-L1, and can release the inhibition on immune cells; the DOX is a chemotherapeutic drug; the 2-DG is a glycolysis inhibitor, and can inhibit the glycolysis process in cells; and the application belongs to the field of medical biotechnology.

A dendritic polymer comprising: (a) a central core; and (b)(i) at least one 2-deoxyglucose surface branching unit conjugated to the central core; or (b)(ii) at least one trehalose surface branching unit conjugated to the central core; or (b)(iii) at least one 2-deoxyglucose surface branching unit conjugated to the central core and at least one trehalose surface branching unit conjugated to the central core.

This invention provides a fluoro-18 labeled p-aminophenylboronic acid, its preparation method, and its application. The fluoro-18 labeled p-aminophenylboronic acid is N-(4-phenylboronic acid)-2-D-fluorodeoxyglucosamine (4-N-[ 18 [F]FDGly-PBA). Among them, fluoro-18 labeled fluorodeoxyglucose can be used for tumor imaging, and p-aminophenylboronic acid can be used for BNCT treatment. Therefore, the fluoro-18 labeled p-aminophenylboronic acid provided by the present invention is a novel dual-targeted diagnostic and therapeutic imaging agent that can be used for tumor PET / CT imaging and BNCT treatment.

The invention relates to the technical field of functional coating materials, and discloses antibacterial and waterproof leather and a preparation method thereof.The antibacterial and waterproof leather comprises a leather base material and a surface coating, and the surface coating comprises 5-15% of waterproof and antibacterial monomers and 40-60% of polytetrahydrofuran glycol derivative polymers; 20 to 35 percent of an isophorone diisocyanate cross-linked product; 3 to 8% of a 2, 5-anhydro-1-azido-1-deoxy-D-glucitol modifier, and the balance of a solvent; the waterproof antibacterial monomer is formed by grafting 2-guanidino benzimidazole and trifluoroepoxypropane through a terminal carboxyl group intermediate; the surface coating is of a gradient structure and comprises a bottom layer, a middle layer and a surface layer. The three-step gradient structure of the bottom layer, the middle layer and the surface layer is constructed, so that collaborative optimization of air permeability, mechanical strength and super-hydrophobicity is realized. The bottom layer with low solid content forms a porous buffer layer, the middle layer provides mechanical support, and the surface layer with high solid content constructs a compact protective network. Antibacterial groups are directionally distributed on an interface layer, and hydrophobic chain segments are enriched on the surface, so that the antibacterial property, the waterproof property and the flexibility are efficiently unified.

The present invention relates to a novel mutant of 5-dehydro-2-deoxyglucono kinase and a method for producing 5'-inosinic acid using the same. In the 5-dehydro-2-deoxyglucono kinase mutant, one or more amino acids in the amino acid sequence constituting 5-dehydro-2-deoxyglucono kinase are substituted, resulting in a change in the activity of the protein, and a recombinant microorganism containing the same can efficiently produce 5'-inosinic acid.

The invention belongs to the technical field of bioengineering, and particularly relates to a lactobacillus casei specific recognition primer and probe based on a deoxyglucuronide isomerase expression gene (COG3718) and application of the lactobacillus casei specific recognition primer and probe. The primer pair comprises an upstream primer (COG3718F1) and a downstream primer (COG3718R1), wherein the upstream primer (COG3718F1) and the downstream primer ( The sequence of the probe is 5 '-CATCCGTTGGCGTTCCAG-3', the 5'end of the probe is marked with an FAM fluorophore, and the 3 'end of the probe is marked with a BHQ1 quenching group; the invention also provides a method for qualitatively and quantitatively detecting the casei casei by using the primer and the probe. The method comprises conventional PCR (Polymerase Chain Reaction) and real-time fluorescent quantitative PCR; the primer and the probe have high specificity under the background of complex florae such as human intestinal tracts and the like, can effectively distinguish the lactobacillus casei from related species thereof, and are suitable for rapid and accurate detection of the lactobacillus casei in human intestinal tract samples, dairy products and other environmental samples.

Provided herein are methods and pharmaceutical compositions for preventing or reducing frequency or severity of convulsions or seizures, particularly epileptic seizures by administration of a therapeutically effective amount of 2-deoxy-D-glucose (2-DG) in combination with a therapeutically effective amount of beta-hydroxybutyrate, or 2-DG with other ketones or metabolic intermediates that increase brain ketones. Also provided are methods and pharmaceutical compositions for reducing severity and progression of traumatic brain injury and deleterious sequelae resulting therefrom in an animal by administration of a therapeutically effective amount of 2-DG in combination with a therapeutically effective amount of beta-hydroxybutyrate, or 2-DG with other ketones or metabolic intermediates that increase brain ketones.

The utility model provides a sampling device for production of deoxidized glucose injection, which comprises a supporting stand column, a sampling device body, a sampling device main body, a sampling device main body, a sampling device main body and a sampling device main body, and is characterized in that a driving motor is fixed at the upper end of the supporting stand column; the mixed reaction barrel is located on the front side of the supporting stand column, the mixed reaction barrel is fixed to the surface of a fixed plate block, and the fixed plate block is connected with the supporting stand column through a movable block; the liquid conveying pipelines are positioned on the left and right sides of the mixed reaction barrel, and the middle parts of the liquid conveying pipelines are connected with micro superchargers; the liquid storage pipe is located at the lower end of the fixing plate, and a liquid taking needle is installed at the lower end of the liquid storage pipe. The device solves the problems that detection liquid has certain corrosion and dangerousness, the safety of sampling personnel is easily harmed because the detection liquid is generally extracted one by one manually during sampling analysis, and the deoxidized glucose injection cannot be detected by mechanical sampling instead of manual sampling.